Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US11242387B2 · kind B2 · utility
0Cited by
116References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 19, 2019 |
| Grant date | Feb 8, 2022 |
| Priority date | — |
| Expiry date | Aug 19, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.